New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
07:13 EDTNKTRNektar initiated with a Buy at Lazard Capital
Lazard Capital believes Nektar's late stage programs are being undervalued by investors. The firm started shares with a Buy rating and $15 price target.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
10:24 EDTNKTRBaxalta launches U.S. availability of hemophilia A treatment ADYNOVATE
Baxalta (BXLT) announced the launch and first shipments of ADYNOVATE, an extended circulating half-life recombinant factor VIII treatment for hemophilia A based on full-length ADVATE. The treatment was approved by the U.S. Food and Drug Administration in November. "Patients living with hemophilia are increasingly looking for and need treatment options that can address their individual needs," said Dr. Michael Tarantino, medical director of the Bleeding & Clotting Disorders Institute. "The simplicity of ADYNOVATE's twice weekly dosing schedule offers an important new option for the hemophilia community, delivering first and foremost on what matters most - bleed protection, while also easing the schedule of their prophylactic treatment." ADYNOVATE was developed through a collaboration with Nektar Therapeutics (NKTR).
November 16, 2015
05:46 EDTNKTRNektar entitled to $10M payment after Adynovate approval, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use